Valuation: Eli Lilly and Company

Capitalization 72TCr 69TCr 64TCr 56TCr 1,01800Cr 61,04400Cr 1,13100Cr 7,90900Cr 2,92900Cr 25,10200Cr 2,70500Cr 2,64500Cr 1,09,78400Cr P/E ratio 2024 *
63x
P/E ratio 2025 * 37.1x
Enterprise value 74TCr 71TCr 66TCr 58TCr 1,04800Cr 62,83600Cr 1,16400Cr 8,14100Cr 3,01500Cr 25,83900Cr 2,78400Cr 2,72200Cr 1,13,00600Cr EV / Sales 2024 *
16.2x
EV / Sales 2025 * 12.5x
Free-Float
99.81%
Yield 2024 *
0.65%
Yield 2025 * 0.75%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.44%
1 week-3.90%
Current month+0.26%
1 month-4.20%
3 months-13.40%
6 months-7.90%
Current year+36.80%
More quotes
1 week
786.37
Extreme 786.3701
841.00
1 month
711.40
Extreme 711.4001
846.46
Current year
579.05
Extreme 579.05
972.53
1 year
561.65
Extreme 561.65
972.53
3 years
231.87
Extreme 231.87
972.53
5 years
117.06
Extreme 117.06
972.53
10 years
64.18
Extreme 64.18
972.53
More quotes
Director TitleAgeSince
Chief Executive Officer 56 01/01/2017
President - -
Director of Finance/CFO 47 09/09/2024
Manager TitleAgeSince
Director/Board Member 64 01/01/2005
Director/Board Member 68 01/04/2009
Director/Board Member 52 12/12/2011
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.38%-3.90%+36.54%+220.87%72TCr
+1.00%+1.32%+18.10%+107.40%49TCr
-1.45%-2.34%-5.24%-12.77%36TCr
-0.75%-1.20%+15.27%+37.81%31TCr
-1.23%-1.38%-4.21%+36.17%26TCr
+0.83%+0.87%+0.63%-31.81%23TCr
+0.25%+0.55%+4.38%+27.76%21TCr
-0.92%-2.40%+2.76%+17.98%20TCr
-0.47%-0.91%+1.32%+30.44%15TCr
-1.23%+0.29%-11.65%-54.16%14TCr
Average -0.45%-1.53%+5.79%+37.97% 30.66TCr
Weighted average by Cap. -0.36%-1.53%+12.08%+73.87%
See all sector performances

Financials

2024 *2025 *
Net sales 4.56TCr 4.35TCr 4.04TCr 3.58TCr 6.45TCr 3,87000Cr 7.17TCr 50TCr 19TCr 1,59100Cr 17TCr 17TCr 6,95900Cr 5.86TCr 5.59TCr 5.18TCr 4.6TCr 8.28TCr 4,96700Cr 9.2TCr 64TCr 24TCr 2,04200Cr 22TCr 22TCr 8,93200Cr
Net income 1.13TCr 1.08TCr 1TCr 889.77Cr 1.6TCr 96TCr 1.78TCr 12TCr 4.61TCr 40TCr 4.26TCr 4.17TCr 1,73000Cr 1.96TCr 1.87TCr 1.73TCr 1.54TCr 2.77TCr 1,65900Cr 3.07TCr 21TCr 7.96TCr 68TCr 7.35TCr 7.19TCr 2,98400Cr
Net Debt 2.11TCr 2.02TCr 1.87TCr 1.66TCr 2.99TCr 1,79200Cr 3.32TCr 23TCr 8.6TCr 74TCr 7.94TCr 7.76TCr 3,22300Cr 1.31TCr 1.25TCr 1.16TCr 1.03TCr 1.85TCr 1,11200Cr 2.06TCr 14TCr 5.33TCr 46TCr 4.92TCr 4.82TCr 1,99900Cr
More financial data * Estimated data
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Employees
43,000
More about the company
Date Price Change Volume
12/24/12 796.61 $ -0.37% 1,778,622
10/24/10 799.58 $ -0.50% 2,695,247
09/24/09 803.58 $ -2.80% 3,175,956
06/24/06 826.71 $ +0.13% 3,047,127
05/24/05 825.62 $ -0.51% 2,423,388

Delayed Quote Nyse, December 12, 2024 at 01:18 am IST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart ELI-LILLY-AND-COMPANYMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
799.58USD
Average target price
984.05USD
Spread / Average Target
+23.07%
Consensus

Quarterly revenue - Rate of surprise